Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
23.53
0.00 (0.00%)
At close: Jul 23, 2026, 4:00 PM EDT
23.07
-0.46 (-1.95%)
Pre-market: Jul 24, 2026, 6:06 AM EDT
Legend Biotech Revenue
Legend Biotech had revenue of $305.10M in the quarter ending March 31, 2026, with 56.46% growth. This brings the company's revenue in the last twelve months to $1.14B, up 56.38% year-over-year. In the year 2025, Legend Biotech had annual revenue of $1.03B with 64.02% growth.
Revenue (ttm)
$1.14B
Revenue Growth
+56.38%
P/S Ratio
4.00
Revenue / Employee
$384,148
Employees
2,965
Market Cap
4.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03B | 401.60M | 64.02% |
| Dec 31, 2024 | 627.30M | 342.20M | 120.03% |
| Dec 31, 2023 | 285.10M | 168.10M | 143.66% |
| Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
| Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
| Dec 31, 2020 | 75.00M | 15.02M | 25.04% |
| Dec 31, 2019 | 59.98M | 10.85M | 22.08% |
| Dec 31, 2018 | 49.13M | 25.54M | 108.24% |
| Dec 31, 2017 | 23.59M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.10B |
| Caris Life Sciences | 907.29M |
| Travere Therapeutics | 536.20M |
| Tango Therapeutics | 56.99M |
| Relay Therapeutics | 10.68M |
| CRISPR Therapeutics AG | 4.10M |
LEGN News
- 2 hours ago - Legend Biotech downgraded to Neutral from Buy at UBS - TheFly
- 11 days ago - Legend Biotech resumed with a Neutral at JPMorgan - TheFly
- 16 days ago - Legend Biotech price target lowered to $63 from $64 at RBC Capital - TheFly
- 5 weeks ago - Legend Biotech falls -14.4% - TheFly
- 5 weeks ago - Legend Biotech falls -12.2% - TheFly
- 5 weeks ago - Legend Biotech 7.7M share Spot Secondary priced at $29.35 - TheFly
- 5 weeks ago - Legend Biotech Corporation Announces Pricing of Public Offering - GlobeNewsWire
- 5 weeks ago - Legend Biotech secondary offering; price range $29.35-$31.35 - TheFly